Objective: Variants in neuronal voltage-gated sodium channel a-subunits genes SCN1A, SCN2A, and SCN8A are common in early onset epileptic encephalopathies and other autosomal dominant childhood epilepsy syndromes. However, in clinical practice, missense variants are often classified as variants of uncertain significance when missense variants are identified but heritability cannot be determined. Genetic testing reports often include results of computational tests to estimate pathogenicity and the frequency of that variant in population-based databases. The objective of this work was to enhance clinicians' understanding of results by (1) determining how effectively computational algorithms predict epileptogenicity of sodium channel (SCN) missense variants; (2) optimizing their predictive capabilities; and (3) determining if epilepsyassociated SCN variants are present in population-based databases. This will help clinicians better understand the results of indeterminate SCN test results in people with epilepsy. Methods: Pathogenic, likely pathogenic, and benign variants in SCNs were identified using databases of sodium channel variants. Benign variants were also identified from population-based databases. Eight algorithms commonly used to predict pathogenicity were compared. In addition, logistic regression was used to determine if a combination of algorithms could better predict pathogenicity. Results: Based on American College of Medical Genetic Criteria, 440 variants were classified as pathogenic or likely pathogenic and 84 were classified as benign or likely benign. Twenty-eight variants previously associated with epilepsy were present in population-based gene databases. The output provided by most computational algorithms had a high sensitivity but low specificity with an accuracy of 0.52-0.77. Accuracy could be improved by adjusting the threshold for pathogenicity. Using this adjustment, the Mendelian Clinically Applicable Pathogenicity (M-CAP) algorithm had an accuracy of 0.90 and a combination of algorithms increased the accuracy to 0.92. Significance: Potentially pathogenic variants are present in population-based sources. Most computational algorithms overestimate pathogenicity; however, a weighted combination of several algorithms increased classification accuracy to >0.90.
At least 10-30% of early onset epileptic encephalopathies (EOEEs) result from single gene mutations. [1] [2] [3] [4] As a result, screening for mutations in multiple genes simultaneously or performing whole exome sequencing is common in the clinical evaluation of children with EOEE. 5 Mutations in voltage-gated sodium channel (SCN) a-subunit genes are the most commonly identified cause of EOEE; with SCN1A 1, 4 and SCN2A 2 being the most frequently identified causative genes. Mutations in the related SCN gene SCN8A have also been associated with EOEE. [1] [2] [3] 6 Sodium channelopathies have a wide spectrum of epilepsy phenotypes; for example, mutations in SCN1A are classically associated with severe myoclonic epilepsy of infancy (SMEI; Dravet syndrome) and a milder autosomal dominant phenotype, generalized epilepsy with febrile seizures plus (GEFS+). 7, 8 Approximately half of SCN1A mutations associated with SMEI are missense and half result in truncation of the protein. In contrast, most mutations associated with SCN2A and SCN8A, and with inherited SCN1A-associated phenotypes are missense mutations. 9 When SCN gene variants are identified in people with epilepsy, additional evaluation to determine pathogenicity is needed, including testing of family members to establish the inheritance pattern. EOEE is typically occurs de novo, whereas milder phenotypes are inherited from an affected parent. Unfortunately family members may not be available. In studies of genetic causes of EOEE and genetic registries of SCN1A mutations, complete parental testing was unavailable in about 10-40% of cases. 1, 10, 11 Therefore, in the absence of a classic clinical presentation or limited corroborative genetic testing, results of the initial genetic evaluation can produce equivocal results, termed variants of unknown significance (VUS). For clinical purposes, the American College of Medical Genetics and Genomics (ACMG) proposed that for classification of variants as likely pathogenic or likely benign, a classification accuracy of 90% is needed.
One "gold standard" for understanding the implications of variants is in vitro demonstration of deleterious effects; however, these electrophysiologic studies are not clinically available. The lack of functional testing is not unique to epilepsy. To address this, computational methods to estimate the likelihood that a mutation is pathogenic have been developed. [12] [13] [14] [15] [16] [17] [18] [19] [20] To gain a better understanding of the pathogenicity of VUS, the purpose of this work is to determine how accurate current computational algorithms are at predicting pathogenicity of missense variants in SCN genes most commonly associated with epilepsy (SCN1A, SCN2A, and SCN8A) and to optimize the effectiveness of these algorithms.
Methods
Potentially pathogenic nonsynonymous missense mutations in SCN1A were identified from two large datasets (Zuberi et al. 21 and http://www.molgen.vib-ua.be/scn1a-mutations/Mutations/Mutations.cfm 22 ), which included information about both phenotype and inheritance. Pathogenic and likely pathogenic variants in SCN2A were obtained from ClinVar (http://www.ncbi.nlm.nih.gov/clin var), the publically accessible portion of HGMD (http:// www.hgmd.cf.ac.uk/ac/) and from the literature. 3, 23, 24 Pathogenic variants in SCN8A were identified from www. scn8a.net and then classified by review of the associated literature. Only epilepsy-associated phenotypes were studied. Two other voltage-gated sodium channels, SCN3A and SCN9, have also been implicated in epilepsy. However, for SCN3A, the phenotypes are less distinct 25 and it is unclear if SCN9A variants are a cause of epilepsy or a modifier of seizure presentation. 26 The number of potentially pathogenic variants in these genes is low, and some of the commercially available panels do not include these genes. Therefore SCN3A and SCN9A were not included in this analysis.
Genetic and phenotypic information on variants that appeared in multiple datasets was combined to better refine the phenotype. Variants were classified as pathogenic, likely pathogenic, variants of uncertain significance, benign, or likely benign according to ACMG guidelines. 27 Likely benign variants were identified from the benign variants in datasets mentioned earlier, and from the Exome Aggregate Consortium (ExAC) database (http://exac.broadinstitute.org) 28 and the 1000 genomes dataset (http://www. 1000genomes.org). The ExAC database is an aggregate of exome sequencing data from a variety of different sequencing projects. It contains sequences from 60,706 unrelated individuals without severe pediatric diseases. These population-based datasets have incomplete phenotyping, so it is possible that some individuals with mild phenotypes such as GEFS+ or benign familial neonatal infantile seizures (BFNIS) could be included. The threshold frequency for inclusion as benign was set at a minor allele frequency (MAF) above the frequency of any pathogenic variant seen in the ExAC dataset (MAF = 0.000058). If a variant was present in a population-based dataset at a frequency above
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• The use of this algorithm may be useful for interpretation of some missense variants if parental DNA samples are unavailable for segregation analysis that of EOEE-associated variants and was present in a disease dataset but was classified as a VUS, it was included as a likely benign variant (based on ACMG criteria).
Eight computational algorithms were used to predict the pathogenicity of variants. These algorithms were selected because they are widely and freely accessible, and provided both categorical and continuous results. The results of some are reported on clinically used epilepsy gene panels (e.g., GeneDx) and have been used in similar studies of cancer and cardiac diseases. 29, 30 Computations were done using the web-based platforms shown in Table 1 . PolyPhen-2 and MutationAssessor3 used graded scales. Initial results from these algorithms were dichotomized. For PolyPhen-2, probably and possibly damaging variants were classified as pathogenic and benign variants were classified as nonpathogenic. PolyPhen-2 has two different models (HumDiv and HumVar). The HumDiv model was selected because it was the algorithm used in analogous cardiac and cancer studies 29, 30 and had fewer intermediate results than the HumVar model. For MutationAssessor3, high-and medium-impact variants were classified as pathogenic and lowand neutral-impact variants were classified as nonpathogenic. This categorization was used previously in comparative studies of these methodologies 29, 30 and in the development of the original algorithm. 19 One algorithm (M-CAP) reported scores only if the variant was an uncommon variant, so for this study, an M-CAP score of zero was used for those common variants. Only variants where all programs provided an output were used in the analysis. Sensitivity, specificity, and classification accuracy were calculated for each algorithm. Classification accuracy was defined here as the average of the sensitivity and specificity. For optimization of algorithms, classification accuracy was selected over the ability of an algorithm to correctly classify individual variants (correct decision) because the correct decision approach would be biased by a greater number of pathogenic SCN variants compared to benign variants.
Several approaches to optimize the classification accuracy of algorithms were used. First the categorical output of the two algorithms that provided graded output was refined. For PolyPhen-2 and Mutation Assessor3, location of the variant within the resultant protein was considered to classify the intermediate categories. Based on the frequency of pathogenic variants in proportion to the size of functional domains in SCN1A, Zuberi et al. 21 demonstrated that nonsynonymous missense mutations occur more frequently in some regions (N-terminus; transmembrane segments S3, S4, S5, and S6; and the pore loop connecting transmembrane segments S5 and S6) of SCN1A than in others (C-terminus, transmembrane segments S1, and S2, cytoplasmic linkers, and linkers between the transmembrane region other than the pore). For PolyPhen-2, the possibly damaging variants were classified as pathogenic if they occurred in regions with a greater than average pathogenic rate and nonpathogenic if in regions with a lower than average pathogenic rate. The medium impact variants in MutationAssessor3 were similarly categorized. A second method was to determine the threshold value of the continuous variables that maximized classification accuracy.
To improve classification, continuous responses from the algorithms were considered as possible explanatory variables in a logistic regression model. The backward elimination variable selection procedure was used to derive a parsimonious model that would best predict the classification of variants. The criterion used was classification accuracy. The resulting model produced a fitted value for probability of disease that we will refer to as the SCN index.
Comparisons of SCN indices between groups were done using the Mann-Whitney U rank sum test, and the Bonferroni correction was applied to correct for multiple comparisons (15 comparisons) . A validation set was identified from different data sources. ClinVar and HGMD were used for SCN1A and SCN8A. Additional SCN1A variants were also identified from http://www.gzneurosci.com/scn1adatabase/index.php. SCN2A variants included in the validation were variants in the professional version of HGMD that were not in the publically accessible version of HGMD. Variants that were in the original dataset were excluded from the validation dataset. Because the phenotype and inheritance were not as readily available in all the sources used for validation, ACMG classification could not be used for all entries; therefore, the variants were classified according to the attribution in the particular datasets. For comparing the validation to the original datasets, the pathogenic and likely pathogenic variants in the original were combined because it is possible that the validation dataset contained both pathogenic and likely pathogenic variants. The classification accuracy, sensitivity, and specificity were calculated using the thresholds optimized from the original dataset. In addition, variants in two epilepsy-associated voltage-gated potassium channel genes, KCNQ2 and KCNQ3, were identified from ClinVar (accessed 9/23/2016).
The datasets were accessed between 8/15/2015 and 9/25/ 2016, and websites for predictive algorithms were accessed between 8/15/2015 and 1/28/2017. SAS version 9.3 (SAS Institute, Inc., Cary, NC, U.S.A.) and Origin 8.1 were used for statistical analyses. This study was exempt from institutional review board (IRB) review.
Results
From the initial disease datasets, 624 unique missense variants were identified (Table S1 ). One was excluded because it interfered with the initiation of the protein and the full battery of in silico testing could not be performed, and two excluded because results were unavailable from one algorithm (M-CAP). Applying ACMG criteria, 440 were categorized as pathogenic or likely pathogenic (SCN1A 343; SCN2A 62; and SCN8A 35), 92 as VUS (SCN1A 45; SCN2A 41; SCN8A 6), and 84 as benign (SCN1A 44; SCN2A 24; SCN8A 16). VUS were most often those identified in the datasets that did not have phenotypes typically associated with sodium channelopathies and had incomplete characterization of inheritance.
Combining the ExAC database, 1000 Genomes database, and benign variants from Zuberi et al., 913 variants were identified (Table S2 ). The majority of those in ExAC occurred only once in the approximately 120,000 alleles sequenced (n = 583). Included in the ExAC database were three SCN1A variants that were in the initial disease datasets identified as SMEI-spectrum phenotype with de novo inheritance and one with a GEFS+ phenotype. The most frequently seen SMEI-associated missense variant in ExAC (SCN1A H127D 21 ) occurred in seven individuals (minor allele frequency = 0.0058%). In addition, a variant of SCN2A (R188W) that had demonstrated altered channel function in electrophysiologic studies in vitro, was seen in the ExAC dataset, occurring in three individuals (MAF 0.0025%). In the absence of the ExAC dataset, these would have been classified as pathogenic. One SCN1A variant (R1596C) continued to be classified as pathogenic based on ACMG criteria, despite its presence in the control dataset (due to additional supporting evidence of pathogenicity), and the others met criteria for likely pathogenic. Of note, although frame-shift variants were not included in this analysis, the ExAC database also contained a frame-shift SCN1A variant (R1912KfsX32; one allele) that had been previously reported de novo in a patient with an SMEI spectrum phenotype. 21 Only one variant in each sodium channel occurred in >1% of the genotypes, and the others were rare with a minor allele frequency of 0.5% or less. Excluding those in ExAC that occurred at a frequency below that associated with likely pathogenic variants, only 84 benign or likely benign variants were identified. Among these 84, based on published literature and ACMG criteria, 8 would have been classified as VUS for epilepsy if they had not appeared in the ExAC database. One variant was associated with familial hemiplegic migraine.
Without optimization, the classification accuracy of predications for various algorithms ranged from 0.52 to 0.77 (Table 2 ). All algorithms except for FATHMM Unweighted had sensitivities of >0.9; however, most had poor specificity, and only one (FATHMM Unweighted) had a specificity >0.7. PolyPhen-2 HumDiv and MutationAssessor3 had the highest accuracy (0.77). PolyPhen-2 HumVar had a similar classification accuracy as PolyPhen-2 HumDiv (0.78). Weighing the output of intermediate findings of MutationAssessor3 and PolyPhen-2 HumDiv for locations within mutation hotspots in SCN1A produced modest improvements in classification accuracy. Adjustment of the threshold value to predict pathogenicity increased the classification accuracy (to 0.77-0.9). This resulted from improvements in specificity (all ≥0.7). With the adjusted threshold, the most accurate algorithm, M-CAP, had a classification accuracy of 0.9.
The most effective optimization strategy was a logistic regression model where the probability of disease was modeled. The prediction algorithms were the independent variables and a backward elimination procedure was used to remove nonstatistically significant variables. The resulting The resulting receiver-operating characteristic (ROC) curve had an area of 0.954. Furthermore, the HosmerLemeshow goodness-of-fit test showed no lack-of-fit (pvalue = 0.82). By comparison, while the area under the ROC for PolyPhen-2 HumDiv alone was 0.85, it showed significant lack-of-fit with the p-value for the HosmerLemeshow test = 0.0001.
The SCN index predicted that 411 (93.4%) of 440 variants classified according to ACMG as pathogenic or likely pathogenic would be pathogenic, only 44 (47.8%) of 92 of VUS would be categorized as pathogenic, and 9 (10.7%) of 84 categorized as benign were predicted to be pathogenic. Consistent with this, values of the SCN index were highest in the pathogenic group and were progressively lower in less clearly pathologic categories ( Fig. 1 and Table 3 ). In the cases where complete inheritance information was present, SCN index was significantly greater in pathogenic and likely pathogenic variants that occurred de novo compared to those that were inherited (p = 0.001). The SCN index was higher for SCN1A than SCN2A (p < 0.001), and there was a trend toward higher SCN index with SCN1A compared to SCN8A, but this did not reach statistical significance. This may represent differences in the classification used in the different data sources used for each channel.
Variants in the ExAC database also had a significantly lower SCN index than pathogenic/likely pathogenic variants (p < 0.001). The ExAC database contained 28 variants that had been previously associated with epilepsy and could be classified as pathogenic (n = 1), likely pathogenic (n = 5), or VUS (n = 22) according to ACMG criteria, including four SCN1A variants that were published as de One hundred thirty-seven unique pathogenic/likely pathogenic and six unique benign variants were identified from validation datasets (Table 4) . Despite the paucity of additional benign variants, classification accuracy for the best performing optimization methods, M-CAP and SCN index, were largely unchanged (with classification accuracies of 0.96; Table 4 ). The SCN index scores were Table 3 . Epilepsia ILAE similar between the original dataset and the validation dataset for both the combined pathogenic/likely pathogenic and the benign groups (p = 1 for both; Table 3 ). Despite the presence of occasional disease-associated variants in the ExAC dataset, given the devastating phenotype of the most pathogenic SCN variants, it is unlikely that these make up a significant proportion of the variants in the ExAC population dataset. Therefore, all variants in ExAC not known to have an association with epilepsy were treated as benign when the optimized versions of each algorithm were compared (Table 4 ). This approach minimized the bias introduced by the large proportion of disease-associated variants in the original and validation datasets (358 of 440 were pathogenic/likely pathogenic). The accuracies of M-CAP and SCN Index were 0.87 and 0.85, respectively. Sixty-five epilepsy-associated variants in SCN1A (n = 45), SCN2A (n = 11), or SCN8A (n = 9) and five variants that were ultimately classified as benign or likely benign (SCN1A n = 1 and SCN2A n = 4) had in vitro functional studies. 9, 11, 31 All of the benign variants had no demonstrable effect on channel biophysics and all optimized algorithms predicted that these would be benign. Of variants with demonstrable functional effects, the optimized algorithms predicted that 75-95% would be pathogenic, and classification accuracies were above 0.95 for the SCN index and optimized versions of M-CAP, SIFT, and PolyPhen-2.
To explore whether the optimization methods used for sodium channels could be generalized to other voltagegated ion channels, variants in KCNQ2 and KCNQ3 were studied. Sixty-eight pathogenic or likely pathogenic variants and 13 benign variants were identified. The SCN-optimized method that had the highest classification accuracy for potassium channels was MutationAssessor3, with a classification accuracy of 0.85 (Table 4) .
Discussion
EOEEs are characterized by difficult to control seizures and developmental regression or retardation with an onset before the first year of life. As genetic causes have become increasingly recognized, sequencing of multiple genes simultaneously is frequently undertaken as part of the evaluation of imaging negative EOEEs. However, our ability to do genetic analysis has progressed faster than our ability to interpret the results. The pathogenicity of de novo null variants (such as nonsense and frameshift variants) requires little supporting evidence, 27 but for missense variants the criteria to establish pathogenicity rely on supportive genetic data, functional evidence, or both. Unfortunately, this supportive evidence is often not available.
Initial reports of SCN1A mutations associated with epilepsy appeared more than a decade ago, 32 and since then hundreds of different pathogenic variants in SCN1A have been identified. More recently, mutations in SCN2A and SCN8A have also been identified in people with EOEE and families with inherited epilepsies. Consequently, it is possible to determine how computer algorithms designed to predict the effect of a missense variant on protein function in general perform more specifically in predicting the epileptogenicity of SCN variants. It is also possible to optimize the categorization of SCN variants.
Without optimization, the algorithms studied here all had a relatively low specificity and thus overestimated the potential pathogenicity of SCN variants. The sensitivity of two algorithms was improved by weighting the intermediate interpretations according to the location within the protein by assigning greater pathogenicity to those variants occurring in the N-terminus, pore region (S5, S5-S6, S6), voltage sensor region (S4), and transmembrane segment S3. This approach requires knowledge of the tertiary structure of the ion channel. Although this information is available, it is often not provided in clinical reports. Another limitation is that it assumes that the proteins encoded by SCN2A and SCN8A have the same distribution of pathogenic variation as SCN1A.
Strategies that optimized the threshold value defining pathogenicity improved the performance of all in silico algorithms so that they all had positive predictive values >0.9, but most algorithms still overestimated the potential deleterious impact of variants. However, the use of optimized paradigms is helpful only if the raw output is available. This is often not the case when reviewing commercial genetic testing reports. Nevertheless, the most accurate simple algorithm for estimation of pathogenicity of sodium channel variants was M-CAP, after the threshold for pathogenicity was adjusted to a level of 0.63. The most accurate optimization method overall, calculation of the SCN index, is the most difficult because it includes continuous output of multiple algorithms. A website is available to make the SCN index easily accessible ( https://www.cincin natichildrens.org/service/c/epilepsy/sn1a). In addition, SCN indices and classifications for most predicted SCN1A, SCN2A, and SCN8A missense variants are listed in Table S3 .
The classification accuracies for sodium channel-related epilepsies were over the 90% threshold set by the ACMG for clinical use for both the SCN index and M-CAP when the latter used the higher threshold value for pathogenicity. However, at least when the threshold optimized for sodium channels was applied to voltage-gated potassium channels, none of the paradigms reached the 90% accuracy proposed by the ACMG.
A major weakness in this approach was the difficulty defining variants as benign or pathogenic. This is explained partially by the lack of available phenotyping in population databases. Surprisingly, although variants associated with severe sporadic epilepsy are under extreme selection bias and as such should not be seen in population datasets of adults free of severe childhood disorders (such as ExAC), these did contain pathogenic variants associated with EOEE. Although relatively rare, some are seen in multiple unrelated persons and have also been identified in unaffected family members of epileptic subjects. 33 Moreover, at least one variant found in the ExAC dataset had demonstrated deleterious effects on channel function in vitro. 34 Although participants are free of severe pediatric diseases, which would include EOEE, people with milder phenotypes such as GEFS+ could be represented. Alternatively, there may be other factors that influence the expression of variants in mildly affected individuals. One approach that could address this issue would be to restrict analysis only to those variants that have functional studies. However, only a limited number of variants have been studied; therefore, this approach is currently not feasible. Further optimization of prediction programs would require greater availability of both pathogenic and benign variants. The number of pathogenic variants in sodium channels continues to increase; however, identification of additional truly benign variants is slower but may become available if large population-based databases with clinical phenotyping become available. The SCN1A, SCN2A, and SCN8A genes are relatively intolerant to mutations, increasing the likelihood that variants in these genes lead to an epilepsy phenotype. 4 This intolerance also means that relatively few benign variants are available. Most of the prediction algorithms used here are based on conservation of genes compared to related genes. As a result of relative intolerance to change and high conservation of the voltage-gated sodium channel genes, as new gene sequences become available and are incorporated into the prediction programs, the prediction scores for these genes are unlikely to change dramatically.
From the clinical prospective, identification of a missense SCN1A, SCN2A, or SCN8A variant in an infant with severe epilepsy should raise suspicion, even if that variant is present at a very low frequency in large population databases. In cases when further confirmatory information such as when parental DNA is unavailable or the clinical phenotype is atypical, certain in silico prediction algorithms such as M-CAP or the SCN index can be helpful. Because the SCN index tends to be lower in milder phenotypes, a high SCN Index in a mild epilepsy phenotype is also suspicious.
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